Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of benzydalysine in preparing medicine for treating diabetic peripheral neuropathy

A technology of peripheral neuropathy and bendalysine, which is applied in the application field of medicine, can solve the problems of no bendalysine and other problems, achieve obvious dose correlation, reduce blood sugar and glycosylated hemoglobin, and stimulate insulin secretion , strong effect

Active Publication Date: 2007-06-20
NANJING MEDICAL UNIV +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there has been no relevant report on the treatment of diabetic peripheral neuropathy by benzyl lysine.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1: Effects of BDL on General Physiological Conditions of DPN Rats

[0040] (1). Materials and methods

[0041] 1 experimental animal

[0042] Male Sprague-Dawley rats, weighing 180-210 g, were provided by Shanghai Slack Experimental Animal Co., Ltd., animal certificate number: SCXK (Shanghai) 2003-0003.

[0043] 2 Drugs, reagents and instruments

[0044] Bendazac lysine (bendazac lysine, BDL) is white powder, molecular weight 428, molecular formula C 6 h 14 N 2 o 2. C 16 h 14 N 2 o 3 , Chemical name: L-Lysine (1-benzyl-1H-indazole-3-oxyl) acetate, provided by Zhejiang Pinghu Shapaisi Pharmaceutical Co., Ltd., batch number Lot030507, and the rest of the reagents are the same as the first part . Streptozotocin (STZ) was purchased from Calbiochem, lot number Lot.B51229. The blood glucose detection kit was purchased from Zhejiang Dongou Bioengineering Co., Ltd., lot number Lot2004030266. Insulin radioimmunoassay kit was purchased from China Institute of...

Embodiment 2

[0061] Example 2 Effect of BDL on Blood Glucose and Glycated Hemoglobin in DPN Rats

[0062] 1. Materials and methods (with embodiment 1)

[0063] 2 results

[0064] Blood glucose and glycosylated hemoglobin (HbA 1 C) significantly higher than the normal control group, with a very significant difference (P1 C Compared with the DPN group, the hypoglycemia was not obvious; while the blood glucose and HbA in the BDL middle and high dose treatment group 1 Compared with DPN group, C showed obvious hypoglycemic effect (P<0.05, P<0.01). The positive drug EPS treatment group had no hypoglycemic effect (see Table 2).

[0065] Table 2. Effects of BDL on blood glucose and glycated protein in DPN rats

[0066] Group n blood sugar (mmol.L -1 ) Glycated protein (%)

[0067] Before administration After administration

[0068] NS 10 (initial) 3.14±0.45 3.69±0.47 7.56±1.43

[0069] DPN 10 15.15±1.45 22.24±6.02 ## 14.30±1.06 ##

[0070] BL10 15.44±0.98 17.89±3.31 ...

Embodiment 3

[0080] Example 3 The inhibitory effect of BDL on nerve tissue AR and erythrocyte AR in DPN rats 1 Materials and methods (same as Example 1)

[0081] 2 results

[0082] AR activity in sciatic nerve and erythrocytes of rats in DPN group was significantly higher than that in normal group (P<0.01), indicating that AR activity in tissue cells was activated during hyperglycemia. The activity of AR in the BDL low, medium and high dose treatment group was lower than that in the DPN group (P<0.01), indicating that BDL had an inhibitory effect on AR. The AR activity of the EPS treatment group was close to that of the BDL medium and high dose group, significantly lower than that of the DPN group (P<0.01), showing a strong inhibitory effect on AR (see Table 4)

[0083] Table 4. Effects of BDL on nerve tissue and erythrocyte aldose reductase in DPN rats

[0084] group

[0085] Note: Compared with the NS group and the DPN group, ## P<0.01; compared with drug treatment group a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses the new application of benzydalysine, and is especially the application of benzydalysine in preparing medicine for treating diabetic peripheral neural lesion. Pharmacodynamic experiment research shows that benzydalysine has obvious functions of lowering blood sugar, saccharifying haemoglobin and promoting insulin secretion, can raise the activity of sciatic nerve GSH-PX, inhibit the activity of COX-2, and has antioxidant and antiphlogistic effect, the effect of lowering AGES content in nerve and serum, etc. Benzydalysine and some supplementary material may be prepared into oral preparation for preventing and treating diabetic peripheral neural lesion.

Description

[0001] 1. Technical field [0002] The present invention relates to a new application of Bendax lysine preparations, in particular to the application of Bendax lysine in the preparation of medicines for treating diabetic peripheral neuropathy. 2. Background technology [0003] Diabetic neuropathy is one of the most common complications of diabetes. The lesion can involve both central and peripheral nerves, especially the latter. At present, more than 50 million people in my country are facing the threat of diabetes. According to statistics, the incidence of peripheral neuropathy in diabetic patients reaches 30%, 60% and 90% after 5 years, 10 years and 20 years respectively. Diabetic neuropathy can affect the central nervous system and peripheral nerves (diabetes peripheral neuropathy, DPN), among which the latter is the most common and seriously affects the quality of life of patients. Clinically, when diabetic patients are complicated with peripheral neuropathy, acral parest...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/415A61K9/08A61K9/10A61K9/16A61K9/20A61K9/48A61P3/10A61P25/02
Inventor 张银娣余俊先沈建平吴建伟金弟陈德康丁虹彬邱俊
Owner NANJING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com